Association of prostate-specific antigen levels and patterns of benign and malignant uptake detected on bone scintigraphy in patients with newly diagnosed prostate carcinoma

Nuclear Medicine Communications

Volumn 21, Issue 7, 2000, Pages 617-622

  Jacobson, A F ^a  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE; BONE TUMOR; CLINICAL TRIAL; HUMAN; IMMUNOLOGY; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SCINTISCANNING;

ADULT; AGED; BONE AND BONES; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M MEDRONATE;

EID: 0034230512     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200007000-00003     Document Type: Review

References (25)

1. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57-60.
2. Chybowski FM, Larson Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145: 313-318.
3. Gleave ME, Coupland D, Drachenberg D et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996; 47: 708-712.
4. O’Donoghue JM, Rogers E, Grimes H et al. A reappraisal of serial isotope bone scans in prostate cancer. Br J Radiol 1993; 66: 672-676.
5. Gerber G, Chodak GW. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer. Urology 1991; 37: 418-422.
6. Miller PD, Eardley I, Kirby RS. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Br J Urol 1992; 70: 295-298.
7. Vijayakumar V, Vijayakumar S, Farhat Quadri S, Blend MJ. Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer? Am J Clin Oncol (CCT) 1994; 17: 432-436.
8. Wolff IM, Ittel T, Boeckmann W et al. Skeletal alkaline phosphatase in the metastatic workup of patients with prostate cancer. Eur Urol 1996; 30: 302-306.
9. Kemp PM, Maguire GA, Bird NJ. Which patients with prostate carcinoma require a staging bone scan? Br J Urol 1997; 79: 611-614.
10. Wolff JM, Bares R, Jung PK et al. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer. Urol Int 1996; 56: 169-173.
11. Rudoni M, Antonini G, Favro M et al. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med 1995; 22: 207-211.
12. Lee CT, Oesterling JE. Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin N Am 1997; 24: 389-394.
13. Haukass S, Roervik J, Halvorsen OJ, Foelling M. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? Br J Urol 1997; 79: 770-776.
14. Levran Z, Gonzales JA, Diokno AC et al. Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol 1995; 75: 778-781.
15. Jacobson AF, Stomper PC, Jochelson MS, Ascoli DM, Henderson IC, Kaplan WD. Association between number and site of new bone scan abnormalities and presence of skeletal metastases in patients with breast cancer. J Nucl Med 1990; 30: 387-392.
16. Jacobson AF, Cronin EB, Stomper PC, Kaplan WD. Bone scans with one or two new abnormalities in cancer patients with no known metastases: Frequency and serial scintigraphic behavior of benign and malignant lesions. Radiology 1990; 175: 229-232.
17. Soloway MS, Hardeman SW, Hickey D et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202.
18. Amico S, Liehn JC, Desoize B et al. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma. Clin Nucl Med 1991; 16: 643-648.
19. Terris MK, Klonecke AS, McDougall IR, Stamey TA. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med 1991; 32: 1713-1717.
20. Hetherington JW, Siddall JK, Cooper EH. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer. Eur Urol 1988; 14: 1-5.
21. Oommen R, Geethanjali FS, Gopalakrishnan G et al. Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate. Br J Radiol 1994; 67: 469-471.
22. Freitas JE, Gilvydas R, Ferry JD, Gonzales JA. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up. J Nucl Med 1991; 32: 1387-1390.
23. Shih WJ, Wierzbinski B, Collins J et al. Correlation of prostate-specific antigen and technetium-99m HMDP bone imaging. Clin Nucl Med 1989; 10: 750-755.
24. Pantelides ML, Bowman SP, George NJR. Levels of prostate specific antigen that predict skeletal spread in prostate cancer. Br J Urol 1992; 70: 299-303.
25. Jacobson AF, Stomper PC, Cronin EB, Kaplan WD. Bone scans with one or two new abnormalities in cancer patients with no known metastases: Reliability of interpretation of initial correlative radiographs. Radiology 1990; 174: 503-507.